New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide

被引：1
|
作者：
Landmesser, Ulf [1 ,2 ,3 ,4 ,5 ]
Makhmudova, Umidakhon [1 ,2 ]
机构：
[1] Deutsch Herzzentrum Charite, Dept Cardiol Angiol & Intens Med, Berlin, Germany
[2] Friede Springer Cardiovasc Prevent Ctr Charite, Berlin, Germany
[3] Partner Site Berlin, German Ctr Cardiovasc Res, Berlin, Germany
[4] Berlin Inst Hlth, Berlin, Germany
[5] Charite Univ Med Berlin, Hindenburgdamm 30, D-12203 Berlin, Germany
来源：
CIRCULATION | 2023年 / 148卷 / 02期
关键词：
Editorials; LDL cholesterol; PCSK9; PCKS9 oral inhibition;
D O I：
10.1161/CIRCULATIONAHA.123.065407
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：159 / 161
页数：3
相关论文
共 50 条
  • [1] BINDING OF PCSK9 TO CIRCULATING LDL: EFFECT OF PCSK9 MONOCLONAL ANTIBODIES ON THE LDL-BOUND PCSK9?
    De Stefano, D.
    Baragetti, A.
    Baragetti, A.
    Macri, N.
    Tavori, H.
    Fazio, S.
    Catapano, A. L.
    ATHEROSCLEROSIS, 2018, 275 : E101 - E101
  • [2] Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
    Shapiro, Michael D.
    Tavori, Hagai
    Oleaga, Carlota
    Miles, Joshua
    Fazio, Sergio
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38
  • [3] Realizing the Potential of PCSK9 Inhibition A Novel Oral Macrocyclic Peptide on the Horizon
    Chapman, M. John
    Packard, Chris J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 81 (16) : 1565 - 1568
  • [4] A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove
    Evison, Benny J.
    Palmer, James T.
    Lambert, Gilles
    Treutlein, Herbert
    Zeng, Jun
    Nativel, Brice
    Chemello, Kevin
    Zhu, Qing
    Wang, Jie
    Teng, Yanfen
    Tang, Wei
    Xu, Yanfeng
    Rathi, Anuj Kumar
    Kumar, Sanjay
    Suchowerska, Alexandra K.
    Parmar, Jasneet
    Dixon, Ian
    Kelly, Graham E.
    Bonnar, James
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (06)
  • [5] STRUCTURE AND TRAFFICKING OF PCSK9 IN LDL BINDING
    Matteucci, Sara
    Pravata, Valentina
    Esposito, Francesco Maria
    Arnaboldi, Lorenzo
    Gianazza, Erica
    Grigore, Liliana
    Banfi, Cristina
    Catapano, Alberico
    ATHEROSCLEROSIS, 2024, 395
  • [6] New prospects for PCSK9 inhibition?
    Landmesser, Ulf
    Chapman, M. John
    Stock, Jane K.
    Amarenco, Pierre
    Belch, Jill J. F.
    Boren, Jan
    Farnier, Michel
    Ference, Brian A.
    Gielen, Stephan
    Graham, Ian
    Grobbee, Diederick E.
    Hovingh, G. Kees
    Luscher, Thomas F.
    Piepoli, Massimo F.
    Ray, Kausik K.
    Stroes, Erik S.
    Wiklund, Olov
    Windecker, Stephan
    Luis Zamorano, Jose
    Pinto, Fausto
    Tokgozoglu, Lale
    Bax, Jeroen J.
    Catapano, Alberico L.
    EUROPEAN HEART JOURNAL, 2018, 39 (27) : 2600 - 2601
  • [7] Back to Basics: PCSK9 as a New Target for the LDL Receptor
    Corral, Pablo
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2014, 102 (01) : E5 - E8
  • [8] The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
    Momtazi-Borojeni, Amir Abbas
    Banach, Maciej
    Ruscica, Massimiliano
    Sahebkar, Amirhossein
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (10) : 1199 - 1208
  • [9] Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor
    Wooten, Catherine J.
    Adcock, Audrey F.
    Agina-Obu, DaTonye I.
    Lopez, Dayami
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2014, 545 : 124 - 132
  • [10] Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book
    Santos, Raul D.
    Rocha, Viviane Z.
    EUROPEAN HEART JOURNAL, 2023, 44 (02) : 139 - 141
12345